A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance

Clinical Infectious Diseases

Volumn 41, Issue 1, 2005, Pages 118-121

  Fuller, Jeffrey D ^a,b   Low, Donald E ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME; CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COMORBIDITY; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MENINGITIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 20844432547     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430829     Document Type: Review

References (32)

1. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-33.
2. Ambrose PG, Bast D, Doern GV, et al. Fluoroquinolone-resistant Streptococcus pneumonias, an emerging but unrecognized public health concern: is it time to resight the goalposts? Clin Infect Dis 2004; 39:1554-6.
3. Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48:2101-7.
4. Jones ME, Blosser-Middleton RS, Thornsberry C, et al. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. Diagn Microbiol Infect Dis 2003; 47:579-86.
5. Mendes C, Kiffer CR, Blosser-Middleton RS, et al. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002. Clin Microbiol Infect 2004; 10:521-6.
6. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, et al. Antimicrobial susceptibilities of 1684 Streptococcus pneumoniae and 2039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001;45:3334-40.
7. Canton R, Morosini M, Enright MC, et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003; 52:944-52.
8. Richter SS, Heilmann KP, Beekmann SE, et al. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 2005; 40:225-35.
9. Powis J, McGeer A, Green K, et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004; 48:3305-11.
10. Karlowsky JA, Jones ME, Draghi DC, et al. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann Clin Microbiol Antimicrob 2004; 3:7.
11. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
12. NCCLS. Performance standards for antimicrobial susceptibility testing. 14th information supplement, M100-S14. Wayne, PA: NCCLS, 2004.
13. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747-50.
14. Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001; 33:517-22.
15. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 347:65-7.
16. Kuehnert MJ, Nolte FS, Perlino CA. Fluoroquinolone resistance in Streptococcus pneumoniae. Ann Intern Med 1999; 131:312-3.
17. Wortmann GW, Bennett SP. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae. Clin Infect Dis 1999; 29:1599-600.
18. Perez-Trallero E, Marimon JM, Iglesias L, et al. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003; 9:1159-62.
19. Anderson KB, Tan JS, File TM Jr, et al. Emergence of levofloxacin- resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37:376-81.
20. Kays MB, Smith DW, Wack ME, et al. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002; 22:395-9.
21. Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001; 184:794-8.
22. Empey PE, Jennings HR, Thornton AC, et al. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001; 35:687-90.
23. Roson B, Carratala I, Fernandez-Sabe N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164:502-8.
24. Pletz MW, McGee L, Burkhardt O, et al. Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis 2004; 24: 58-60.
25. Kupronis BA, Richards CL, Whitney CG. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51:1520-5.
26. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32:701-7.
27. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A, for the Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288-97.
28. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:630-1.
29. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-9.
30. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45:2793-7.
31. Low DE. Fluoroquinolone-resistant pneumococci: maybe resistance isn't futile? Clin Infect Dis 2005;40:236-8.
32. Lim S, Bast D, McGeer A, et al. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 2003; 9:833-7.